Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Novartis acquires optogenetics startup Arctos

by Ryan Cross
September 24, 2021 | A version of this story appeared in Volume 99, Issue 35

 

Novartis has acquired the small Swiss start-up Arctos Medical, which is developing optogenetic gene therapies to treat blindness. The therapies deliver into the eye a gene for a light-sensing protein that could partially restore the ability to see, even if a person’s photoreceptors are dead. Novartis says the approach might work for many forms of genetic and age-related blindness. The company acquired another optogenetics start-up, Vedere Bio, in October 2020.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.